A Study to Look at How a Single Oral Dose of 14C-OSI-906 is Absorbed, Broken Down and Eliminated in the Body

A Phase 1, Open-label Study to Investigate the Absorption, Metabolism, and Excretion of 14C-OSI-906 in Subjects With Advanced Solid Tumors With an Optional Treatment Phase

The purpose of this study is to evaluate the pharmacokinetics, in particular the routes of excretion and extent of metabolism of OSI-906 after a single oral dose of 14C-labeled OSI-906. Subjects with Advanced Solid Tumors may participate and then continue into the Optional Treatment Phase.

Study Overview

• Status: Completed
• Conditions: Advanced Solid Tumors; Pharmacokinetics of 14C-OSI-906
• Intervention / Treatment: Drug: radio-labeled OSI-906; Drug: OSI-906

Detailed Description

This study includes two parts: Part A

Subjects will be admitted to the clinical research unit on Day -1 and remain confined to the unit until post dosing discharge criteria are met up to a maximum of 10 days. On Day 1, subjects will receive a single oral dose of 14C-labeled OSI-906.

Part B (optional)

Once the subject has completed part A, the subject may elect to continue participation in Part B. Subjects will receive OSI-906 (non-radiolabeled) twice daily by mouth. Subjects will be seen for scheduled visits every 7 days for the first 36 days and then every 21 days.

• Study Type: Interventional
• Enrollment (Actual): 5
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Washington
    • Tacoma, Washington, United States, 98405
      • Northwest Medical Specialties, PLLC
    • Tacoma, Washington, United States, 98418
      • Comprehensive Clinical Development NW, Inc.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• The subject has histologically or cytologically confirmed diagnosis of advanced solid tumor (measurable or non-measurable disease) for which no conventional therapy is available
• The subject has an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 2
• The subject has a predicted life expectancy ≥12 weeks
• The subject has a fasting glucose ≤125 mg/dL (7 mmol/L) at Screening, Day -1 and pre-dose Day 1

• The subject has adequate organ function defined by the following laboratory parameters:

  • absolute neutrophil count (ANC) ≥1.5 x 10 9/L
  • platelet count ≥100 x 10 9/L
  • total bilirubin ≤1.5 x upper limit of normal (ULN)
  • aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN, or ≤ 5 x ULN if subject has documented liver metastases
  • serum creatinine ≤1.5 x ULN
  • potassium, calcium, and magnesium within normal limits or determined by the investigator to be not clinically significant (NCS)
• The subject has a negative cotinine test
• If male, is surgically sterile, or is using a medically acceptable method to prevent pregnancy and agrees to continue using this method while participating in the study and for 90 days after the last dose of study medication
• If female, the subject is surgically sterile or status post hysterectomy, post-menopausal, or is using 2 forms of medically acceptable methods of birth control, one of which must be a barrier method to prevent pregnancy and agrees to continue using this method from screening until 90 days after the last dose of study medication
• If female, the subject must not be breastfeeding at Screening, during the study period and for 90 days after last dose of study drug administration
• If female, the subject must not donate ova starting at Screening, and throughout the study period and for 90 days after last dose of study drug administration
• Female subject of child bearing potential has a negative pregnancy test at Screening and Day -1

Exclusion Criteria:

• The subject has Type 1 or Type 2 diabetes mellitus currently requiring insulinotropic or insulin therapy
• The subject has a history of poorly controlled gastrointestinal disorder (s) that could affect the absorption or metabolism of study drug
• The subject has used IGF-1R inhibitor therapy in last 6 months
• The subject has hepatocellular carcinoma
• The subject has used a CYP1A2 inhibitor or inducer within 14 days prior to Day 1
• The subject has used drugs with a risk of causing QTc interval prolongation and Torsade de Pointes (TdP) within 14 days prior to Day 1
• The subject has a history (within last 6 months) of significant cardio-vascular disease
• The subject has a history (within the last 6 months) of significant arrhythmia disease, unless the disease is well-controlled with medication per the Principal Investigator's clinical judgment
• The subject has had major surgery ≤ 3 weeks prior to Day 1
• The subject has had radiation ≤ 3 weeks prior to Day 1
• The subject has had chemotherapy ≤ 3 weeks prior to Day 1
• The subject has participated in a radiolabeled study in the last 12 months
• The subject has a history of cerebrovascular accident (CVA) within 6 months prior to Day 1 or that resulted in ongoing neurologic instability
• The subject has an active infection or serious underlying medical condition (including any type of active seizure disorder within 12 months prior to Day 1) that would impair the ability of the subject to receive study drug
• The subject has participated in any interventional clinical study within 21 days or has been treated with any investigational drugs within 30 days or 5 half lives whichever is longer, prior to the initiation of Screening
• The subject has a history of any psychiatric condition that might impair the subject's ability to understand or to comply with the requirements of the study or to provide informed consent
• The subject is pregnant or lactating
• The subject has symptomatic brain metastases that are not stable, require steroids, or that have required radiation and/or other related treatment, (i.e., anti-epileptic medication) within 28 days prior to Day 1
• The subject has a history of allergic reactions attributed to compounds of similar chemical or biologic composition to the study drug

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: OSI-906; Two Parts: Part A: 14C-labeled OSI-906 Part B: (Optional) OSI-906 (non-labeled)	Drug: radio-labeled OSI-906; Part A: oral solution of 14C-OSI-906; Drug: OSI-906; Part B: oral tablets OSI-906

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Radioactivity in whole blood and plasma	Outcome measure for Part A: Area under the time concentration curve extrapolated to infinity (AUCinf), AUC from time of dosing to last quantifiable time point (AUClast), Maximum Plasma Concentration (Cmax), Time to maximum concentration (Tmax), Terminal half-life (t 1/2), Apparent Body Clearance after dosing (CL/F), and Apparent volume of distribution (Vz/F)	Up to 10 days from time of receipt of 14C-labeled OSI-906
Radioactivity ratio in blood/plasma	Outcome Measure for Part A of OSI-906 distribution between cellular components and plasma	Up to 10 days from time of receipt of 14C-labeled OSI-906
Excretion ratio and cumulative excretion of radioactivity in urine and feces	Outcome measure for Part A	Up to 10 days from time of receipt of 14C-labeled OSI-906
Composite of Pharmacokinetics of OSI-906 in plasma: AUC inf, AUC last, C max, t max, t 1/2, CL/F, and Vz/F	Outcome measure for Part A	Up to 10 days from time of receipt of 14C-labeled OSI-906
Composite of Pharmacokinetics of OSI-906 in urine: Cumulative amount of drug excreted into urine, feces or bile up to collection time of last measurable concentration (Ae last), Renal Clearance (CL R), and percentage of dose excreted (Ae last%)	Outcome measure for Part A	Up to 10 days from time of receipt of 14C-labeled OSI-906

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Metabolic Profile: Profiling of possible metabolites in OSI-906 plasma, urine, and feces	Outcome measure for Part A	Up to 10 days from time of receipt of 14C-labeled OSI-906
Safety as assessed by recording adverse events, laboratory assessments and vital signs, and electrocardiograms (ECGs)	Outcome measures for Part A and Part B	For Part A: Days 1-10 and/or 30 days post treatment visit. For Part B: Treatment Period 1 (TP1) through 30 day post treatment visit (up to two years)

Collaborators and Investigators

• Sponsor: Astellas Pharma Global Development, Inc.
• Investigators: Study Director: Medical Director, Astellas Pharma Global Development

Publications and helpful links

Helpful Links

• Link to results on the Astellas Clinical Study Results website

Study record dates

Study Major Dates

• Study Start (Actual): March 19, 2012
• Primary Completion (Actual): December 8, 2012
• Study Completion (Actual): February 20, 2013

Study Registration Dates

• First Submitted: February 7, 2012
• First Submitted That Met QC Criteria: February 8, 2012
• First Posted (Estimated): February 9, 2012

Study Record Updates

• Last Update Posted (Actual): November 7, 2024
• Last Update Submitted That Met QC Criteria: November 6, 2024
• Last Verified: October 1, 2024

More Information

Terms related to this study

• Keywords: mass balance; OSI-906; oncology patients; Metabolic profile of 906; Pharmacokinetics of 14C-OSI-906; Cancer, solid tumors; Absorption, Metabolism, and Excretion of OSI-906
• Other Study ID Numbers: OSI-906-104

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.